Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Proteomics International Laboratories Ltd. ( (AU:PIQ) ) has provided an update.
Proteomics International Laboratories has appointed David Morris as Chief Executive Officer and Managing Director, effective 19 January 2026, marking a leadership transition from founder Dr Richard Lipscombe, who retires after 25 years but will assist during a handover period. Morris, a seasoned healthcare and medtech executive with experience at Cochlear, Nanosonics, Polynovo and Monash IVF, is being brought in to drive commercial execution and international market penetration of the company’s Promarker diagnostic pipeline, with a remuneration package heavily weighted to performance-based short- and long-term incentives, underscoring the board’s focus on translating its precision diagnostic technology into global commercial growth for patients and shareholders.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.63 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd, a wholly owned subsidiary and trading name of PILL (ASX: PIQ), is a Perth-based medical technology company focused on precision diagnostics and bio-analytical services. Leveraging expertise in proteomics—the large-scale study of protein structure and function—the company develops its Promarker diagnostic platform to improve disease prediction and management, targeting global markets across the Americas, Europe and Asia.
Average Trading Volume: 378,714
Technical Sentiment Signal: Buy
Current Market Cap: A$108.9M
For a thorough assessment of PIQ stock, go to TipRanks’ Stock Analysis page.